TABLE 1.
Patient characteristics.
| Characteristic | Overall (n = 496) | Institution A (n = 313) | Institution B (n = 59) | Institution C (n = 124) | p * | ||
|---|---|---|---|---|---|---|---|
| Gender | 0.196 | ||||||
| Male | 427 (86.1%) | 269 (85.9%) | 47 (79.7%) | 111 (89.5%) | |||
| Female | 69 (13.9%) | 44 (14.1%) | 12 (20.3%) | 13 (10.5%) | |||
| Hepatitis B | 0.428 | ||||||
| Yes | 417 (84.1%) | 268 (85.6%) | 49 (83.1%) | 100 (80.6%) | |||
| No | 79 (15.9%) | 45 (14.4%) | 10 (16.9%) | 24 (19.4%) | |||
| Age (y) | 0.019 | ||||||
| ≤55 | 321 (64.7%) | 217 (69.3%) | 33 (55.9%) | 71 (57.3%) | |||
| >55 | 175 (35.3%) | 96 (30.7%) | 26 (44.1%) | 53 (42.7%) | |||
| ALBI grade | 0.523 | ||||||
| 1 | 251 (50.6%) | 163 (52.1%) | 26 (44.1%) | 62 (50.0%) | |||
| 2 | 245 (49.4%) | 150 (47.9%) | 33 (55.9%) | 62 (50.0%) | |||
| Child–Pugh grade | 0.430 | ||||||
| A | 430 (86.7%) | 273 (87.2%) | 48 (81.4%) | 109 (87.9%) | |||
| B | 66 (13.3%) | 40 (12.8%) | 11 (18.6%) | 15 (12.1%) | |||
| Maximum tumor size (cm) | 0.417 | ||||||
| <5 | 194 (39.1%) | 119 (38.0%) | 27 (45.8%) | 48 (38.7%) | |||
| 5–10 | 180 (36.3%) | 118 (37.7%) | 22 (37.3%) | 40 (32.3%) | |||
| >10 | 122 (24.6%) | 76 (24.3%) | 10 (16.9%) | 36 (29.0%) | |||
| Lobes involved | 0.852 | ||||||
| Unilobar | 318 (64.1%) | 198 (63.3%) | 38 (64.4%) | 82 (66.1%) | |||
| Bilobar | 178 (35.9%) | 115 (36.7%) | 21 (35.6%) | 42 (33.9%) | |||
| No. of lesions | 0.779 | ||||||
| 1 | 225 (45.4%) | 144 (46.0%) | 28 (47.5%) | 53 (42.7%) | |||
| >1 | 271 (54.6%) | 169 (54.0%) | 31 (52.5%) | 71 (57.3%) | |||
| ECOG | 0.090 | ||||||
| 0 | 482 (97.2%) | 307 (98.1%) | 58 (98.3%) | 117 (94.4%) | |||
| 1 | 14 (2.8%) | 6 (1.9%) | 1 (1.7%) | 7 (5.6%) | |||
| PVTT | 0.005 | ||||||
| None | 309 (62.3%) | 194 (62.0%) | 44 (74.6%) | 71 (57.3%) | |||
| Branch | 102 (20.6%) | 71 (22.7%) | 11 (18.6%) | 20 (16.1%) | |||
| Main | 85 (17.1%) | 48 (15.3%) | 4 (6.8%) | 33 (26.6%) | |||
| BCLC stage | 0.071 | ||||||
| B | 252 (50.8%) | 156 (49.8%) | 38 (64.4%) | 58 (46.8%) | |||
| C | 244 (49.2%) | 157 (50.2%) | 21 (35.6%) | 66 (53.2%) | |||
| AFP (ng/dl) | 0.760 | ||||||
| ≤200 | 257 (51.8%) | 159 (50.8%) | 33 (55.9%) | 65 (52.4%) | |||
| >200 | 239 (48.2%) | 154 (49.2%) | 26 (44.1%) | 59 (47.6%) | |||
| AST (U/L) | 0.138 | ||||||
| ≤40 | 218 (44.0%) | 129 (41.2%) | 25 (42.4%) | 64 (51.6%) | |||
| >40 | 278 (56.0%) | 184 (58.8%) | 34 (57.6%) | 60 (48.4%) | |||
| ALT (U/L) | 0.134 | ||||||
| ≤40 | 284 (57.3%) | 174 (55.6%) | 30 (50.8%) | 80 (64.5%) | |||
| >40 | 212 (42.7%) | 139 (44.4%) | 29 (49.2%) | 44 (35.5%) | |||
*
The chi-square test was used. ALBI, albumin–bilirubin; ECOG, Eastern Cooperative Oncology Group; PVTT, portal vein tumor thrombosis; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; AST, aspartate transaminase; ALT, alanine transaminase.